LEXICON PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Mar 7, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 7, 2025
LXRX$1.86+2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except par value and share amounts)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $66,656 | $22,465 |
| Short-term investments | 171,301 | 147,561 |
| Accounts receivable, net | 3,473 | 1,010 |
| Inventory | 231 | 381 |
| Prepaid expenses and other current assets | 4,532 | 5,130 |
| Total current assets | 246,193 | 176,547 |
| Property and equipment, net of accumulated depreciation and amortization of $2,086 and $4,538, respectively | 2,484 | 1,987 |
| Goodwill | 44,543 | 44,543 |
| Operating lease right-of-use-assets | 4,832 | 5,524 |
| Other assets | 368 | 828 |
| Total assets | $298,420 | $229,429 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $14,801 | $14,389 |
| Accrued liabilities | 30,447 | 17,157 |
| Total current liabilities | 45,248 | 31,546 |
| Long-term debt, net | 100,298 | 99,508 |
| Other long-term liabilities | 6,924 | 5,265 |
| Total liabilities | 152,470 | 136,319 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' Equity: | ||
| Preferred stock, $0.01 par value; 5,000,000 shares authorized | ||
| Series A Convertible preferred stock; 2,304,147 shares issued and none outstanding at December 31, 2024; no shares issued or outstanding at December 31, 2023 | — | — |
| Common stock, $0.001 par value; 450,000,000 shares authorized; 363,020,303 and 245,792,668 shares issued, respectively | 363 | 245 |
| Additional paid-in capital | 2,117,325 | 1,862,558 |
| Accumulated deficit | (1,967,242) | (1,766,839) |
| Accumulated other comprehensive income | 119 | 31 |
| Treasury stock, at cost, 1,528,008 and 867,973 shares, respectively | (4,615) | (2,885) |
| Total stockholders' equity | 145,950 | 93,110 |
| Total liabilities and stockholders’ equity | $298,420 | $229,429 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.